Artelo Biosciences (ARTL) Competitors $7.20 +0.11 (+1.56%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$6.85 -0.34 (-4.74%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. GELS, VYNE, AIMD, SYBX, EDSA, ERNA, BLRX, IBIO, ALLR, and NXTCShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Gelteq (GELS), VYNE Therapeutics (VYNE), Ainos (AIMD), Synlogic (SYBX), Edesa Biotech (EDSA), Eterna Therapeutics (ERNA), BioLineRx (BLRX), iBio (IBIO), Allarity Therapeutics (ALLR), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors Gelteq VYNE Therapeutics Ainos Synlogic Edesa Biotech Eterna Therapeutics BioLineRx iBio Allarity Therapeutics NextCure Artelo Biosciences (NASDAQ:ARTL) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings. Is ARTL or GELS more profitable? Gelteq's return on equity of 0.00% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Artelo BiosciencesN/A -104.59% -94.06% Gelteq N/A N/A N/A Do analysts prefer ARTL or GELS? Artelo Biosciences currently has a consensus price target of $33.00, suggesting a potential upside of 358.65%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ARTL or GELS? In the previous week, Artelo Biosciences had 2 more articles in the media than Gelteq. MarketBeat recorded 7 mentions for Artelo Biosciences and 5 mentions for Gelteq. Gelteq's average media sentiment score of 0.94 beat Artelo Biosciences' score of -0.18 indicating that Gelteq is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gelteq 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in ARTL or GELS? 0.9% of Artelo Biosciences shares are owned by institutional investors. 0.8% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation and earnings, ARTL or GELS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtelo BiosciencesN/AN/A-$9.29M-$2.99-2.41GelteqN/AN/AN/AN/AN/A Does the MarketBeat Community prefer ARTL or GELS? Artelo Biosciences received 51 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformArtelo BiosciencesOutperform Votes5177.27% Underperform Votes1522.73% GelteqN/AN/A SummaryArtelo Biosciences beats Gelteq on 8 of the 11 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.61M$6.88B$5.57B$8.51BDividend YieldN/A2.49%5.27%4.16%P/E Ratio-2.518.4626.7519.65Price / SalesN/A262.48404.17152.19Price / CashN/A65.8538.2534.64Price / Book1.756.526.964.59Net Income-$9.29M$143.26M$3.23B$248.23M7 Day Performance7.07%-0.21%-1.23%-1.07%1 Month Performance27.57%10.62%6.34%2.59%1 Year Performance-12.47%3.63%33.04%13.50% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.1022 of 5 stars$7.20+1.6%$33.00+358.7%-12.5%$23.61MN/A-2.515News CoverageAnalyst DowngradeStock SplitShort Interest ↓Gap DownGELSGelteqN/A$1.50-6.3%N/AN/A$14.16MN/A0.00N/APositive NewsGap DownVYNEVYNE Therapeutics2.4775 of 5 stars$0.93-2.3%$6.25+573.5%-60.9%$14.12M$605K-1.0830Short Interest ↑High Trading VolumeAIMDAinos1.1806 of 5 stars$0.63-6.5%N/A-42.7%$14.02M$106.21K-0.4940Positive NewsGap DownSYBXSynlogic1.2634 of 5 stars$1.19+3.7%N/A-22.8%$13.94M$8K-0.2980Upcoming EarningsShort Interest ↑Gap UpEDSAEdesa Biotech3.343 of 5 stars$1.99+1.5%$21.00+955.3%-56.8%$13.76MN/A-1.0620Positive NewsShort Interest ↓ERNAEterna Therapeutics0.9045 of 5 stars$0.22+0.5%N/A-92.0%$13.66M$535K-0.0310Stock SplitShort Interest ↓Gap DownBLRXBioLineRx3.6109 of 5 stars$4.10-21.9%$26.00+534.1%-82.4%$13.65M$22.34M-0.4740Positive NewsGap DownHigh Trading VolumeIBIOiBio1.116 of 5 stars$0.82+6.6%$4.30+423.8%-63.6%$13.56M$375K0.00100Gap DownALLRAllarity Therapeutics0.5337 of 5 stars$0.89+3.2%N/A-94.1%$13.49MN/A0.0010News CoverageNXTCNextCure4.6476 of 5 stars$0.48-2.5%$3.50+628.7%-57.4%$13.47MN/A-0.2390Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Gelteq Alternatives VYNE Therapeutics Alternatives Ainos Alternatives Synlogic Alternatives Edesa Biotech Alternatives Eterna Therapeutics Alternatives BioLineRx Alternatives iBio Alternatives Allarity Therapeutics Alternatives NextCure Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
